Estimating drug efficacy and viral dynamic parameters: HIV and HCV

Statistics in Medicine

Volumn 27, Issue 23, 2008, Pages 4647-4657

  Perelson, Alan S ^a   Ribeiro, Ruy M ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

HCV; Hepatitis C; HIV; Parameter estimation; Viral dynamics

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; PEGINTERFERON; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DYNAMICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NONHUMAN; TIME SERIES ANALYSIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE;

HEPACIVIRUS; HEPATITIS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, STATISTICAL; TREATMENT OUTCOME;

EID: 53849135263     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3116     Document Type: Article

References (41)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
2. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122.
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-1586.
4. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191.
5. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. Latent infection of CDC4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine 1999; 5:512-517.
6. Perelson AS. Modelling viral and immune system dynamics. Nature Reviews Immunology 2002; 2:28-36.
7. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23:366-371.
8. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226-231.
9. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107.
10. Perelson AS, Kirschner DE, De Boer R. Dynamics of HIV infection of CD4+ T cells. Mathematical Biosciences 1993; 114:81-125.
11. Kepler TB, Perelson AS. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proceedings of the National Academy of Sciences USA 1998; 95:11514-11519.
12. Perelson AS, Nelson PW. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Review 1999; 41:3-44.
13. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37: 1343-1350.
14. Louie M, Hogan C, Di Mascio M, Hurley A, Simon V, Rooney J, Ruiz N, Brun S, Sun E, Perelson AS, Ho DD, Markowitz M. Determining the relative efficacy of highly active antiretroviral therapy. Journal of Infectious Diseases 2003; 187:896-900.
15. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, Markowitz M, Moore JP, Perelson AS, Ho DD. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999; 354:1782-1785.
16. Perelson AS, Essunger P, Ho DD. Dynamics of HIV-1 and CD4+ lymphocytes in vivo. Aids 1997; 11:S17-S24.
17. Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM, Bucy RP. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. Journal of Experimental Medicine 1999; 189:1545-1554.
18. Notermans DW, Goudsmit J, Danner SA, de Wolf F, Perelson AS, Mittler J. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. Aids 1998; 12:1483-1490.
19. Wu H, Mellors J, Ruan P, McMahon D, Kelleher D, Lederman MM. Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors. Journal of Acquired Immune Deficiency Syndromes 2003; 33:557-563.
20. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, Perelson AS. Modeling plasma virus concentration during primary HIV infection. Journal of Theoretical Biology 2000; 203:285-301.
21. Holte SE, Melvin AJ, Mullins JI, Tobin NH, Frenkel LM. Density-dependent decay in HIV-1 dynamics. Journal of Acquired Immune Deficiency Syndromes 2006; 41:266-276.
22. Han C, Chaloner K, Perelson AS. Bayesian analysis of a population HIV dynamic model. In Case Studies in Bayesian Statistics, Gatsonis C et al. (eds). Springer: Berlin, 2002; 223-237.
23. Wu H, Huang Y, Acosta EP, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. Journal of Acquired Immune Deficiency Syndromes 2005; 39:272-283.
24. Herrmann E, Zeuzem S, Sarrazin C, Hinrichsen H, Benhamou Y, Manns MP, Reiser M, Reesink H, Calleja JL, Forns X, Steinmann GG, Nehmiz G. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antiviral Therapy 2006; 11:371-376.
25. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. Journal of Infectious Diseases 2000; 182:28-35.
26. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358.
27. Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, Feinstone SM, Neumann AU. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 2005; 128:1056-1066.
28. Dahari H, Lo A, Ribeiro RM, Perelson AS. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. Journal of Theoretical Biology 2007; 247:371-381.
29. Powers KA, Dixit NM, Ribeiro RM, Golia P, Talal AH, Perelson AS. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Seminars in Liver Disease 2003; 23(Suppl. 1):13-18.
30. Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M, Markatou M, Perelson AS. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 2006; 43:943-953.
31. Wu H, Huang Y, Acosta EP, Park JG, Yu S, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. Journal of Pharmacokinetics and Pharmacodynamics 2006; 33:399-419.
32. Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, Perelson AS. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001; 34:1012-1020.
33. Ribeiro RM, Lo A, Perelson AS. Dynamics of hepatitis B virus infection. Microbes and Infection 2002; 4:829-835.
34. Ciupe SM, Ribeiro RM, Nelson PW, Dusheiko G, Perelson AS. The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proceedings of the National Academy of Sciences USA 2007; 104:5050-5055.
35. Ciupe SM, Ribeiro RM, Nelson PW, Perelson AS. Modeling the mechanisms of acute hepatitis B virus infection. Journal of Theoretical Biology 2007; 247:23-35.
36. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. Journal of Experimental Medicine 1999; 190:177-182.
37. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proceedings of the National Academy of Sciences USA 2000; 97:8039-8044.
38. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. Journal of Virology 2006; 80:7590-7599.
39. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
40. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales Jr FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Chaneac M, Reddy KR. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. Journal of Hepatology 2005; 43:425-433.
41. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. Journal of Hepatology 2005; 43:250-257.